Oct 29, 2020
Therapeutic Solutions International Launches Clinical Trial to Validate First Blood Based Predicator of Suicidal Ideation: The Campbell Score(TM)
Oct 28, 2020
JadiCell(TM) Stem Cells Licensed by Therapeutic Solutions International for Brain Injury Significantly Increased Survival of COVID-19 Patients in Double Blind FDA Clinical Trial
Oct 27, 2020
Therapeutic Solutions International Identifies New Mechanism of Mesenchymal Stem Cell Treatment of Brain Injury
Oct 12, 2020
Therapeutic Solutions International Appoints Serena Robella as Director of Sales
Oct 05, 2020
Therapeutic Solutions International announced today appointment of J Christopher Mizer to the Advisory Board of its Campbell Neurosciences Division
Sep 24, 2020
Therapeutic Solutions International Announces Proof of Concept Data and Patent Filing for Neuroleukin(TM): The First Immune Based Suicide Prevention Biological Therapy
Sep 14, 2020
Therapeutic Solutions International Files Comprehensive Campbell Platform(TM) Patent for Stem Cell Immunotherapy of Schizophrenia
Aug 28, 2020
Therapeutic Solutions International Reports Synergistic Suppression of Suicide-Associated Neuroinflammatory Pathway by QuadraMune(TM) and Minocycline
Aug 05, 2020
Therapeutic Solutions International Reports Reduction of Inflammation Associated Memory Impairment by QuadraMune(TM) Administration
Jul 28, 2020
Therapeutic Solutions International Files Patent on Ability of QuadraMune Ingredient Pterostilbene to Reduce Inflammation while Stimulating Brain Protective Biological Pathways
Jul 07, 2020
Therapeutic Solutions International Submits Publication on StemVacs(TM) Preclinical Data Supporting COVID-19 Indication